The Journal of Urology · 1998 · 32 citations · 13 references
MedicineCell BiologyOncologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCancer ProgressionMalignant NeoplasmsProstate CancerSignal Transduction In CancerTumor BiologyCell Division ControlCell-cycle Checkpoint RegulationRetinoblastoma Family ProteinsRetinoblastoma Protein PathwayRetinoblastoma Protein Pathway ModulationRetinoblastoma Protein SignalingRetinoblastoma-related Protein Pathway
PURPOSE: To investigate the effects of brefelding A (BFA) on the growth of the androgen-independent human prostate cancer PC-3 cells, focusing on cell cycle regulation. MATERIALS AND METHODS: BFA is a fungal macrocyclic lactone with an antiviral activity. PC-3 cells were cultured with various concentrations of BFA for indicated times and cell growth was monitored at each time point. Cell cycle analysis was performed to explore the mechanism of BFA-induced growth inhibition. To further investigate the cell cycle regulation, cell cycle-controlling factors, such as the retinoblastoma gene product (pRB) and its regulatory components cdk2, cdk4, and cyclin D1, were analyzed by Western immunoblots. RESULTS: BFA was a potent growth inhibitor at a concentration of 30 ng./ml., resulting in a > 70% reduction in cell number at 3 days. Cell cycle analysis revealed a cell arrest in the G1 to S phase transition. Western blots further showed that BFA induced dephosphorylation of pRB accompanied by down regulation of cdk2, cdk4, and cyclin D1 expression. The extended pRB dephosphorylation in control cell lysates was also observed by the addition of BFA-treated lysates, but was prevented by the inclusion of phosphatase inhibitors in assay mixtures. CONCLUSION: These results suggest that BFA may be a potent cell cycle modulator, which post-translationally regulates pRB phosphorylation possibly by down-regulating cdk2, cdk4, and cyclin D1 and/or by up-regulating a phosphatase(s) capable of dephosphorylating pRB. Thus, BFA-induced growth inhibition in PC-3 cells appears to be at least partially due to the modulation of a pRB-mediated growth pathway.
13
LNCaP model of human prostatic carcinoma.
Julius S. Horoszewicz, Susan S. Leong, Elzbieta Kawinski et al. · PubMed · 1983 · 1.8K citations
Medicine, Cancer Biology, Oncology +15
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn Me, Narayan Ks, Yuko Ohnuki et al. · PubMed · 1979 · 1.6K citations
Isolation of a human prostate carcinoma cell line (DU 145)
Kenneth R. Stone, Don D. Mickey, Heidi Wunderli et al. · International Journal of Cancer · 1978 · 1.2K citations